Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
2(18%)
Results Posted
167%(5 trials)
Terminated
3(27%)

Phase Distribution

Ph early_phase_1
1
9%
Ph not_applicable
1
9%
Ph phase_2
5
45%
Ph phase_3
3
27%

Phase Distribution

1

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
3(30.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(4)
Completed(3)
Terminated(4)

Detailed Status

Completed3
Terminated3
Not yet recruiting2
Recruiting1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (10.0%)
Phase 25 (50.0%)
Phase 33 (30.0%)
N/A1 (10.0%)

Trials by Status

not_yet_recruiting218%
recruiting19%
withdrawn19%
active_not_recruiting19%
completed327%
terminated327%

Recent Activity

2 active trials
Showing 5 of 11
completedphase_2

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

NCT02340676
recruiting

Extracorporeal Photopheresis in Sezary Syndrome

NCT05157581
not_yet_recruitingearly_phase_1

Extracorporeal Photopheresis (ECP) in the Treatment of Stiff Person Syndrome (OPTION Study)

NCT06703333
completedphase_3

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
active_not_recruitingphase_3

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

NCT02181257
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02340676Phase 2

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

Completed
NCT05157581

Extracorporeal Photopheresis in Sezary Syndrome

Recruiting
NCT06703333Early Phase 1

Extracorporeal Photopheresis (ECP) in the Treatment of Stiff Person Syndrome (OPTION Study)

Not Yet Recruiting
NCT03112603Phase 3

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Completed
NCT02181257Phase 3

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

Active Not Recruiting
NCT04986605Phase 2

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis

Not Yet Recruiting
NCT05333029Phase 2

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

Withdrawn
NCT04446182Phase 2

Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD

Terminated
NCT02524847Phase 3

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

Terminated
NCT02322190Phase 2

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Terminated
NCT02226068Not Applicable

Photophoresis Versus Ciclosporine in Severe Atopic Dermatitis

Completed

All 11 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
11